Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 13
Submit an article Journal homepage
131
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Long-Term Effects of ABCB1 and SXR SNPs on the Systemic Exposure to Cyclosporine in Pediatric Kidney Transplant Patients

Mariano Ferraresso1 Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy. ;2 Division of General & Vascular Surgery, St Joseph Hospital, 20122, Milan, ItalyCorrespondence[email protected]
,
Mirco Belingheri3 Division of Pediatric Nephology & Kidney Transplantation, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
,
Stefano Turolo4 Laboratory of Clinical Chemistry & Microbiology, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
,
Luciana Ghio3 Division of Pediatric Nephology & Kidney Transplantation, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
,
Amedea Silvia Tirelli4 Laboratory of Clinical Chemistry & Microbiology, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
,
Paolo Grillo5 Epidemiology Unit, Department of Occupational & Environmental Health, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
,
Marta Lepore3 Division of Pediatric Nephology & Kidney Transplantation, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
&
Alberto Edefonti3 Division of Pediatric Nephology & Kidney Transplantation, Ca‘ Granda Foundation, Ospedale Maggiore, IRCCS, Milan, Italy
 show all
Pages 1605-1613 | Received 03 May 2013, Accepted 25 Jul 2013, Published online: 02 Oct 2013

References

  • Meier-Kriesche HU , LiS, GruessnerRW et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am. J. Transplant. 6(5 Pt 2) , 1111–1131 (2006).
  • Marks SD . How have the past 5 years of research changed clinical practice in paediatric nephrology?. Arch. Dis. Child.92(4) , 357–361 (2007).
  • Kovarik JM , MuellerEA, RichardF et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 62(6) , 759–763 (1996).
  • Keown P , LandsbergD, HalloranP et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 62(12) , 1744–1752 (1996).
  • Barone G , BunkeCM, ChocMG et al. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group. Transplant. Proc. 28(4) , 2183–2186 (1996).
  • del Mar Fernández De Gatta M , Santos-BuelgaD, Domínguez-GilA, GarcíaMJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet.41(2) , 115–135 (2002).
  • Matas AJ , GillinghamKJ, ChaversBM et al. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin. Transplant. 10(6 Pt 1) , 482–486 (1996).
  • Zhang Y , BenetLZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet.40(3) , 159–168 (2001).
  • Dai Y , IwanagaK, LinYS et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem. Pharmacol.68(9) , 1889–1902 (2004).
  • Saeki T , UedaK, TanigawaraY, HoriR, KomanoT. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem.268(9) , 6077–6080 (1993).
  • Hesselink DA , Van Schaik RH, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74(3) , 245–254 (2003).
  • Anglicheau D , ThervetE, EtienneI et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther.75(5) , 422–433 (2004).
  • Thervet E , AnglicheauD, LegendreC, BeauneP. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug Monit.30(2) , 143–150 (2008).
  • Eng HS , MohamedZ, CalneR et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 69(10) , 1858–1864 (2006).
  • Hesselink DA , van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. Pharmacogenomics6(4) , 323–337 (2005).
  • Liu Y , JiW, YinY et al. The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions. Clin. Chim. Acta 403(1–2) , 142–144 (2009).
  • Zhou C , VermaS, BlumbergB. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl. Recept. Signal7 , e001 (2009).
  • Gosden RG , FeinbergAP. Genetics and epigenetics – nature‘s pen-and-pencil set. N. Engl. J. Med.356(7) , 731–733 (2007).
  • Wong AH , GottesmanII, PetronisA. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Hum. Mol. Genet.14(Spec. No. 1) , R11–R18 (2005).
  • Stevens JC , HinesRN, GuC et al. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307(2) , 573–582 (2003).
  • Miki Y , SuzukiT, TazawaC, BlumbergB, SasanoH. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol. Cell. Endocrinol.231(1–2) , 75–85 (2005).
  • Turolo S , TirelliAS, FerraressoM et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol. Rep. 62(6) , 1159–1169 (2010).
  • Zeger SL , LiangKY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics42(1) , 121–130 (1986).
  • Kearns GL , Abdel-RahmanSM, AlanderSW, BloweyDL, LeederJS, KauffmanRE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N. Engl. J. Med.349(12) , 1157–1167 (2003).
  • Michaud J , DubéP, NaudJ et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br. J. Pharmacol. 144(8) , 1067–1077 (2005).
  • Sun H , HuangY, FrassettoL, BenetLZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos.32(11) , 1239–1246 (2004).
  • Nolin TD , AppiahK, KendrickSA, LeP, McmonagleE, HimmelfarbJ. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J. Am. Soc. Nephrol.17(9) , 2363–2367 (2006).
  • Naud J , MichaudJ, LeblondFA, LefrancoisS, BonnardeauxA, PichetteV. Effects of chronic renal failure on liver drug transporters. Drug Metab. Dispos.36(1) , 124–128 (2008).
  • Fanta S , JönssonS, BackmanJT, KarlssonMO, HoppuK. Developmental pharmacokinetics of ciclosporin – a population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol.64(6) , 772–784 (2007).
  • Ushijima K , UemuraO, YamadaT. Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome. Eur. J. Pediatr.171(4) , 663–668 (2012).
  • Sakaeda T , IijimaK, NozuK et al. Prediction of systemic exposure to cyclosporine in Japanese pediatric patients. J. Hum. Genet. 51(11) , 969–976 (2006).
  • Whitington PF , EmondJC, WhitingtonSH, BroelschCE, BakerAL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N. Engl. J. Med.322(11) , 733–738 (1990).
  • Dunn S . Neoral use in the pediatric transplant recipient. Transplant. Proc.32(Suppl. 3A) , S20–S26 (2000).
  • Cooney GF , HabuckyK, HoppuK. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin. Pharmacokinet.32(6) , 481–495 (1997).
  • Takahashi H , IshikawaS, NomotoS et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther. 68(5) , 541–555 (2000).
  • de Wildt SN , KearnsGL, SieSD, HopWC, van den Anker JN. Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin. Drug Investig.23(1) , 27–38 (2003).
  • Marshall J , RodarteA, BlumerJ, KhooKC, AkbariB, KearnsG. Pediatric pharmacodynamics of midazolam oral syrup. Pediatric Pharmacology Research Unit Network. J. Clin. Pharmacol.40(6) , 578–589 (2000).
  • Noda T , TodaniT, WatanabeY, YamamotoS. Liver volume in children measured by computed tomography. Pediatr. Radiol.27(3) , 250–252 (1997).
  • Johnson TN , TuckerGT, TannerMS, Rostami-HodjeganA. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl.11(12) , 1481–1493 (2005).
  • Björkman S . Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol.59(6) , 691–704 (2005).
  • Fanta S , NiemiM, JönssonS et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet. Genomics 18(2) , 77–90 (2008).
  • Crettol S , VenetzJP, FontanaM et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18(4) , 307–315 (2008).
  • Fanta S , JönssonS, KarlssonMO et al. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J. Clin. Pharmacol. 50(5) , 581–597 (2010).
  • Ferraresso M , TuroloS, BelinghieriM et al. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatr. Transplant. 16(6) , 658–663 (2012).
  • Bai S , LiuJ, LuSK, BrunnerLJ. In vivo induction of hepatic P-glycoprotein by cyclosporine in the rat. Res. Commun. Mol. Pathol. Pharmacol.109(1–2) , 103–114 (2001).
  • Hauser IA , KoziolekM, HopferU, ThévenodF. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int.54(4) , 1139–1149 (1998).
  • Jetté L , BeaulieuE, LeclercJM, BéliveauR. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol.270(5 Pt 2) , F756–F765 (1996).
  • Gallagher WM , TweatsD, KoenigJ. Omic profiling for drug safety assessment: current trends and public–private partnerships. Drug Discov. Today14(7–8) , 337–342 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.